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Abstract  23 
CONTEXT: Many biomarkers are associated with type 2 diabetes (T2D) risk 24 
in epidemiological observations. The aim of this study was to identify and summarize current 25 
evidence for causal effects of biomarkers on T2D.  26 
DESIGN AND METHODS:  A systematic literature search in PubMed and EMBASE (until 27 
April 2015) was done to identify Mendelian randomization studies that examined potential 28 
causal effects of biomarkers on T2D. To replicate the findings of identified studies, data from 29 
two large-scale genome-wide association studies (GWAS) were used: 1) DIAbetes Genetics 30 
Replication And Meta-analysis (DIAGRAMv3) for T2D, and 2) the Meta-Analyses of 31 
Glucose and Insulin-related traits Consortium (MAGIC) for glycaemic traits. GWAS 32 
summary statistics were extracted for the same genetic variants (or proxy of variants) which 33 
were used in the original Mendelian randomization studies.  34 
RESULTS: Ten out of 21 biomarkers (from 28 studies) have been reported to be causally 35 
associated with T2D in Mendelian randomization. Most biomarkers were investigated in a 36 
single cohort study or population. Of the 10 biomarkers that were identified, nominally 37 
significant associations with T2D or glycaemic traits were reached for those genetic variants 38 
related to bilirubin, pro-B-type natriuretic peptide, Delta-6 desaturase and dimethylglycine 39 
based on the summary data from DIAGRAMv3 or MAGIC. 40 
CONCLUSIONS: Several Mendelian randomization studies investigated the nature of 41 
associations of biomarkers with T2D. However, there were only few biomarkers that may 42 
have causal effects on T2D.  Further research is needed to broadly evaluate the causal effects 43 
of multiple biomarkers on T2D and glycaemic traits using data from large-scale cohorts or 44 
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Over the past decade, much interest in studying biological markers (biomarkers) for type 2 55 
diabetes (T2D) has been attracted. This happened because multiple pathobiological processes 56 
may contribute to the disease progression, which provides an opportunity to introduce 57 
preventive and therapeutic interventions for T2D 
1
. In clinical practice, such biomarkers (e.g.,  58 
glucose and glycated haemoglobin tests) are widely used for diagnosis of diabetes or for 59 
monitoring of therapeutic intervention 
2, 3
.Targeted intervention at biomarker level would be 60 
useful where there is evidence for a causal relationship between an exposure (like a 61 
biomarker) and T2D 
4
.  62 
Traditional epidemiological studies lack sufficient information to fill the evidence gap due 63 
to unmeasured confounding or reverse causality
4-7
. It has been successfully shown that a 64 
complementary analysis of genetic data, termed “Mendelian randomization”, has additive 65 
value to infer a causal association
4-8
. The main assumption for Mendelian randomization is 66 
that the genetic variants do not change over time and are inherited randomly (based on 67 
Mendel’s laws). In other words, the genetic variants as proxy measures for exposures (e.g., 68 
biomarkers) are essentially considered free from confounding and reverse causation. 69 
Therefore, the analysis of integrated observational-genetic data is considered similar to that of 70 
the randomized trials
9, 10
. In Mendelian randomization, if there is a causal association between 71 
a biomarker and T2D, the genetic variant(s) influencing biomarker and the outcome of 72 
interest should be associated 
5, 6, 8
. In the current study, evidence for causal associations 73 
between biomarkers and the risk of T2D was updated via a systematic literature search to 74 
identify Mendelian randomization studies. Next, summary data from two largest genome-75 
wide association studies (GWAS) for T2D or glycaemic traits
10, 11
 were used to examine the 76 





 Search strategy for candidate biomarkers 80 
PubMed and EMBASE were searched to identify Mendelian randomization studies 81 
examining the associations between biomarkers and T2D until April 2015. The overview of 82 
this systematic literature search was conducted in accordance with the Preferred Reporting 83 
Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, when applicable
12
. A 84 
manual search was also done for the references of included articles to identify other relevant 85 
studies. Because a review of published original studies was performed, the Declaration of 86 
Helsinki items related to “approval of medical ethics committee” and “permission 87 
acquisition” are not applicable to the current study. 88 
 89 
 Selection criteria 90 
Studies were included if: 1) they formally quantified a causal association between one or 91 
more biomarkers (as main exposures) and T2D (as the main outcome); 2) used data on 92 
biomarker-associated genetic variants: 3) and classified/defined the exposure as a biomarker 93 
that has been objectively measured in serum, plasma or urine. The following MeSH key 94 
words or related terms were used: “Diabetes mellitus, Type 2[Mesh]”, Type 2 95 
Diabetes[tiab], Diabetes[ti]; and “Mendelian randomization”, “Mendelian randomisation”, 96 
“instrumental variable”, “genetic risk score” or “causal association”.   97 
 98 
 Data extraction and quality assessment  99 
A primary plan was made to extract necessary data from the full text of the original studies 100 
or to contact the corresponding author(s) when appropriate. Figure 1depicts the work-flow of 101 
the literature search. T2D was determined as the main outcome if one or more of the 102 
following conditions were fulfilled: 1) a physician diagnosed T2D as indicated by self-report 103 
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or in primary-care database; 2) fasting plasma glucose ≥7.0 mmol/l, a random sample plasma 104 
glucose ≥11.1 mmol/l; or  3) initiation of glucose-lowering medication as retrieved from a 105 
pharmacy registry or hospital records
11
.  106 
 107 
Statistical analysis 108 
All genetic variants that affect identified biomarkers were obtained from the original 109 
Mendelian randomization studies. To replicate the nature of relationship between each 110 
biomarker and the outcome (i.e., T2D or glycaemic traits), a genetic approach using outcome-111 
association data for the biomarker-related genetic variants was applied 
5, 6, 8
. In brief, to 112 
determine whether the same genetic variants (or a suitable proxy variant) were associated with 113 
T2D (or glycaemic traits), the corresponding summary association statistics from GWAS for 114 
T2D (DIAbetes Genetics Replication And Meta-analysis [DIAGRAMv3])
13
 and glycaemic 115 
traits (Meta-Analyses of Glucose and Insulin-related traits Consortium [MAGIC]) 
14
were 116 
extracted. DIAGRAMv3 is a meta-analysis of multiple GWAS with a total number of 12,171 117 
diabetes cases and 56,862 controls of European descent
13
. Previously, details regarding the 118 
use of GWAS data for Mendelian randomization were described
5, 6, 10, 11
. These selected 119 
single-test association analyses in the GWAS data are equivalent to that of individual-level 120 
data analysis 
5, 6, 11
.  121 
Extracted data were tabulated on Excel spreadsheets. All statistical analyses were 122 
conducted using Excel or Stata/SE version 13.1 for Windows (http://cran.r-project.org/). A 123 





Literature search and study characteristics 127 
After scanning 812 titles and selected abstracts, 33 articles were selected for full text review 128 
11, 15-46
. The literature search process is shown in Figure 1. Five studies were excluded as they 129 
did not measure a specific biomarker (n=1) or investigated a measure of insulin resistance as 130 
the main exposure (n=4)
15, 38-40, 43
. The characteristics of the 28 studies are summarized in 131 
Table 1.The studies were performed in different populations; most were cohort studies 132 
included middle-aged adults in the US or Europe and were published between 2008-2015. 133 
Four studies were conducted only in Asian populations including Chinese or Taiwanese. In 12 134 
studies, data from multiple GWAS were combined to examine the associations between 135 
genotypes and T2D. Six of these studies used data from DIAGRAMv2 (n=3)
47
 or 136 
DIAGRAMv3 (n=3)
13
, and the other six used at least two cohorts with genome-wide 137 
genotyping. DIAGRAMv2 was a meta-analysis of eight GWAS comprising 8,130 individuals 138 
with T2D and 38,987 controls of European descent
47
. All Mendelian randomization studies 139 
investigated only one biomarker as an exposure in relation to T2D. Some studies also 140 







.  In the final sample, 142 
studies included up to 28144/76344 T2D cases/controls or total participants.  143 
 144 
Biomarkers and Mendelian randomization 145 
From 28 studies, data were retrieved on causal associations of biomarkers with T2D. In 146 
these studies, 21 unique biomarkers that were investigated at least once (16 biomarkers), 147 
twice (three biomarkers) and three times (two biomarkers) were identified (Table 1). Nineteen 148 
biomarkers were completely investigated in independent studies. However, the two 149 
biomarkers with three Mendelian randomization studies were investigated in combined 150 
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studies where the same sample , e.g. DIAGRAMv2 for adiponectin
19, 43
, or a part of whole 151 
cohort, e.g. EPIC-Potsdam for vitamin D
17, 45
, were used to make total cases/controls. Eleven 152 
studies used one genetic variant as a single instrumental variable in Mendelian randomization. 153 
Eight studies used at least two independent genetic variants in the same locus as instrumental 154 
variables. The rest of nine studies used multiple genetic variants in different loci or created a 155 
multi-locus genetic risk score for each biomarker. 156 
In main or sensitivity analyses, four studies 
11, 26, 44, 45
 examined causal associations of 157 
bilirubin, Lipoprotein(a), vitamin D, interleukin 1 receptor antagonist (with corresponding 158 
biomarker-associated genotypes) with type 2 diabetes using the DIAGRAMv3 summary data. 159 
In Table 1, the value for each causal estimate can be interpreted as odds ratio (OR), hazard 160 
ratio (HR) or log OR (β coefficient) for diabetes per one unit change in genetically 161 
determined biomarkers or biomarker-associated genotypes. Evidence of causal association 162 
was reported for adiponectin, bilirubin, N-terminal pro B-type natriuretic peptide (NT 163 
proBNP), Delta-6 desaturase (D6D), dimethylglycine, ferritin (Transmembrane protease 164 
serine 6), homocysteine, macrophage migration inhibitory factor (MIF), sex hormone binding 165 
protein (SHBG) and resistin (Table 1). For adiponectin, causal estimates were calculated as an 166 
OR of 0.86 per allele
35
 or a β coefficient of 0.3 for adiponectin multi-locus genotypic risk 167 
score 
19
. Causal estimate for bilirubin was reported as an OR of 0.58 per 1-SD genetically 168 
increased log-transformed bilirubin
11













, the expected ORs for T2D were 0.96, 0.64, 1.1, 0.79, 1.74 and 1.38 per 170 
each copy of risk alleles or genotypes, respectively. For homocysteine, causal estimates were 171 
reported as an OR of 1.29 per 5μmol/L genetically increased homocysteine24, or ORs of 1.93 172 
and 1.52 for CC and CC/TT genotypes
25
, respectively. For SHBG, the expected ORs for T2D 173 
were 0.92 per each copy of the SHBG lowering allele
34
 or 0.3 per 1-SD genetically increased 174 
natural log-transformed in SHBG
21
.  175 
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Using the GWAS data from DIAGRAMv3 or MAGIC 
13, 14
, associations of the genetic 176 
variants influencing these biomarkers with T2D and glycaemic traits were tested. A nominally 177 
significance (P <0.05) was reached for the genetic variants that affect bilirubin (P=0.03 for 178 
glucose and HOMA-IR), NT proBNP (P=0.03 for T2D), D6D activity (P=0.003 for T2D; 179 
P=2.7×10
-8
 for glucose) and dimethylglycine (P=0.004 for glucose) in relation to T2D or 180 
glycaemic traits (Table 2). For adiponectin, a nominally significant association with T2D or 181 
glycaemic traits was observed for seven out of 19 genetic variants. All these seven variants, 182 
except rs12637534, were non-ADIPOQ adiponectin genetic variants . In line with previous 183 
Mendelian randomization studies, the overall effect of non-ADIPOQ variants on T2D or 184 
glycaemic traits together with null association of ADIPOQ variants is compatible with 185 
pleiotropic effects of adiponectin on T2D
42




Discussion  188 
This literature search of Mendelian randomization studies shows here that 10 out of 21 189 
identified biomarkers were reported to be causally associated with T2D. In particular, the 190 
presence of potential causal associations (defined as nominally significant) between the 191 
biomarker-related variants and T2D and/or glycaemic traits can be confirmed for four 192 
biomarkers using the publically-available GWAS data. The inconsistency between the 193 
identified studies and the summary data from DIAGRAMv3 or MAGIC can be to some extent 194 
explained by different design and populations applying across studies, the possibility of false 195 
positive associations, the heterogeneity in T2D, the use of varied sources to ascertain T2D 196 
cases, and differences in data quality control and pre-analysis preparations 
6, 11
. 197 
Taken together, these findings support that the oxidative stress system (bilirubin or 198 
metabolites of bilirubin), the BNP hormone system, D6D activity, and dimethylglycine may 199 
contribute to the development of diabetes or insulin resistance through secondary effects ( i.e., 200 
pleiotropy) or direct mechanisms
11, 37, 42
. Bilirubin that is the major end-product of heme 201 
catabolism has antioxidant properties and may compensate the oxidative stress
11, 48
. Oxidative 202 
stress has been shown as an important factor in the pathophysiology of diabetes
11
. At the 203 
cellular level, bilirubin can be oxidized to its precursor, biliverdin, to detoxify excess of 204 
oxidants. Biliverdin is rapidly recycled to bilirubin via the action of biliverdin reductase, 205 
generating a physiologic cytoprotective cycle in several tissues
49
.  The underlying mechanism 206 
of a protective role of BNP in the aetiology of T2D is unknown in humans
37
. In mice, over-207 
expressed BNP signalling cascade can protect against diet-induced insulin resistance and 208 
obesity through promoting muscle mitochondrial biogenesis and fat oxidation
37, 50
. The 209 
biological mechanisms of the relationship between D6D activity T2D are not well 210 
understood
30
. Although data of human experimental studies are scarce, observational studies 211 





. Since D6D catalyses the synthesis of fatty acids, one can 213 
speculate that the link between D6D activity and T2D is likely to be mediated by changes in 214 
fatty acid composition, which in turn may affect insulin signalling and receptor binding 215 
affinities
30
. Dimethylglycine is metabolized to glycine by dimethylglycine dehydrogenase 216 
(DMGDH) in mammals
32
. Accordingly, a recent GWAS identified that the DMGDH genetic 217 
variants were strongly associated with blood-based dimethylglycine
53
. Epidemiological 218 
studies have observed an inverse association between the precursor of dimethylglycine – 219 
betaine – and metabolic risk factors
54
, but a positive association of elevated glycine with 220 
increased insulin sensitivity
32
. In humans, cardiometabolic effects of inhibition of DMHDH or 221 
supplementation of dimethylglycine have not been investigated
32
. However, experimental 222 
animal studies have suggested a protective role of dimethylglycine in glucose metabolism 223 
through reduction in DMGDH function
32, 55, 56
.  224 
In the post-omics era, epidemiological studies basically suggest that the levels of a 225 
given biomarker differ between patients with T2D (or the individuals at high risk for 226 
developing diabetes) and individuals without diabetes 
2, 57
. If the biomarker is not causally 227 
related to the disease outcome, the process of developing diabetes may cause the increase or 228 




. Unmeasured confounding or measured confounding factors with errors (for example, 230 
physical activity by self-report) is another explanation for the observed associations between 231 
most biomarkers and T2D. In this context, the use of genetic data (like in Mendelian 232 
randomization) can enhance the likelihood that association between a biomarker and T2D is 233 
causal or not, where biomarkers are subject to the evaluation of causal inference 
4, 36, 37
. It 234 
remains to be further confirmed for the potential role of biomarkers in the development of 235 
T2D and the trajectories of glycaemic traits using longitudinal analysis 
6, 11
. The latter 236 
analytical approach can provide insight into potential value of biomarkers which indicate 237 
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pathobiological signals of metabolic changes in the aetiology of T2D. T2D is influenced by 238 
interactions of multiple genes or a gene may have been mapped to multiple biomarkers other 239 
than the biomarker of interest 
4, 13, 14
. Thus, an extensive knowledge of gene function, 240 
biological processes and that the genome interacts with environmental factors is needed to 241 
better understand how genetic variations in the human genome contributes to lifelong risk of 242 
T2D 
4, 11, 13, 14, 57
.  243 
In this review, most studies only investigated a single biomarker-diabetes association 244 
and statistically significant associations are reported more often. Here publication bias should 245 
be considered. Other limitations include lack of complementary analyses in the genetic 246 
associations for glycaemic traits, and that set of genetic variants or large-scale GWAS for 247 
biomarkers were scare. Similarly, the Mendelian randomization approach using GWAS 248 
summary statistics can be extended as a secondary analysis of several datasets that have data 249 
on the biomarker-associated variants (or their proxies) for several diseases or traits. This 250 
multi-disciplinary research requires that a large group of consortia are contacted to obtain 251 
summary association statistics from GWAS consortia for outcomes of interest. Moreover, for 252 
the biomarkers linked to T2D, underlying biological mechanisms remain unknown. To 253 
uncover the underlying mechanisms, one needs to perform a complementary strand of 254 
experimental research. Before that, an in-silico functional gene network (pathway) analysis 255 
can be used to speculate on the possible biological mechanisms of biomarker-disease 256 
associations
58, 59
. Finally, Mendelian randomization cannot completely control for the 257 
possibility of developmental compensation, called canalization, confounding and pleiotropic 258 
effects 
5, 6, 8, 11, 37
.  259 
In conclusion, this is the first study that updates evidence for causal associations between 260 
biomarkers and T2D to date. Several Mendelian randomization studies investigated the nature 261 
of associations of biomarkers with T2D. Most biomarkers were investigated in a single cohort 262 
14 
 
study or population. However, there are only few biomarkers that may have causal effects on 263 
T2D. Further research is warranted to broadly evaluate the causal effects of multiple 264 
biomarkers on T2D and glycaemic traits using data from large-scale cohorts or combined 265 
GWAS including many different genetic variants. This genetic approach may advance our 266 
understanding of the causes of T2D, and potentially enable us to explore novel targets for the 267 
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Table 1: Mendelian randomization studies for biomarkers and type 2 diabetes 
Biomarkers No. of 
Study 
Study Country/year Cases/ 
total or controls 








US, Europe/2013 15960/64731 rs17300539,rs1736653,rs3774261,rs
3821799/ADIPOQ 
Null  
BHS, CUDAS, FDS Australia/2013 967/2355 rs12637534, rs16861209, 
rs17366568/ADIPOQ 
OR,0.86 per allele 

















Beta-carotene 133 WTCCC, DGI, 
FUSION 
US, Europe/2009 4549/5579  rs6564851/BCMO1 Null  
Bilirubin 111 PREVEND Netherlands/ 2015 210/3381 rs6742078/UGT1A1 OR, 0.58 1-sd 




French, Swiss 1 , 
Swiss 2, Austrian, 
MONICA, INCA, 
UK 
US, Europe/2011 23382/57898 rs198389/NPPB OR, 0.96 C allele 
C-reactive protein 116 Whitehall II  UK/2008 354/ 5274 rs1130864, rs1205, rs3093077/ CRP Null  
Delta-6 desaturase 130 EPIC-Potsdam  Germany/2011 673/2724 rs174546/FADS1 RR, 0.64 TT genotype 
Dimethylglycine 132 MDC-CC, MDC, 
MPP 
Sweden/2015 4201/33898 rs2431332/ DMGDH OR, 1.1 A allele 
Ferritin/TMPRSS6 122 Beijing China/2012 272/1574 rs855791, rs4820268/ TMPRSS6 OR, 0.79 AG haplotype 
Fetuin-a 127 CHS US/2013 259/3093 rs4917, rs2248690/AHSG Null  
Homocysteine 224, 25 Hangzhou  China/2014 774/500 rs1801131/MTHFR, 
rs4646356/PEMT 
OR,1.93, 1.52 CC, CT+TT 
- Europe,Asia, 
Africa/2013 
4011/ 4303 rs12134663, rs1801133/MTHFR  OR,1.29 5μmol/L 
IL-1Ra 126 DIAGRAMv3 and 
EPIC-InterAct 
US, Europe/2015 18715/61692 rs6743376, rs1542176/IL1RN Null  
24 
 





Lipoprotein(a) 229, 44 Danish general 
population 
Denmark/2014 2157/28567 rs10455872/LPA Null  
DIAGRAMv3,EPIC-
Norfolk 





Germany/2008 502/1632  rs1007888/MIF HR, 1.74 C allele 
miRNAs 141 Harbin China/2015 995/967 rs895819/miR-27a, rs531564/miR-
124a, rs2910164/miR-146a 
Null  
Resistin 118 CVDFACTS Taiwan/2014 230/3400 rs3745367,rs1423096/RETN OR, 1.38 GG 
Sex hormone binding 
globulin 
221, 34 WTCCC, Dundee, 
EFS-Y2D, Danish, 






 27657/58481 rs1799941/SHBG OR, 0.92 G allele 
WHS US/2009 359/359 rs6259/SHBG OR, 0.3 1-sd 
Triglycerides 120 Go-DARTS 
 










Uric acid 136 Cambridgeshire, 
ADDITION-Ely, 
Norfolk Diabetes 
UK/2011 7504/ 8560 rs12129861/ PDZK1, 
rs742132/LRRC16A, 
rs505802/SLC22A12, rs12356193/ 
SLC16A9, rs17300741/ SLC22A11, 
rs1165151/ SLC17A1, rs2231142/ 
ABCG2, rs734553/ SLC2A9 
Null  









EPIC-Potsdam Germany/2013 1572/2121 rs2282679,rs1155563,rs12785878,rs
3829251,rs10741657,rs6013897,rs6











Vitamin D binding protein 131 CaMos Canada/2014 201/2254 rs2282679/DBP GC Null  
 
  
OR, odds ratio; RR, relative risk; HR, hazard ratio; BNP, brain natriuretic peptide, interleukin 1 receptor antagonist (IL1-Ra) 695 
 696 
DIAGRAM, DIAbetes Genetics Replication And Meta-analysis; EPIC-InterAct, European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct; ARIC, 697 
Atherosclerosis Risk in Communities; WTCCC, Welcome Trust Case Control Cohort; FUSION, Finland-US Investigation of NIDDM genetics 698 
 699 
BHS, Busselton Population Health Survey; CUDAS, Carotid Ultrasound Disease Assessment Study; FDS, Fremantle Diabetes Study  700 
 701 
PREVEND, Prevention of Renal and Vascular End-stage Disease;   702 
 703 
iNCA, iNsuffisance CAdiaque; MONICA, Multinational Monitoring of Trends and Determinants in Cardiovascular Disease  704 
 705 
MDC, Malmö Diet and Cancer Study; MDC-CC, Malmö Diet and Cancer Cardiovascular Cohort; MPP, Malmö Preventive Project; 706 
CVDFACTS , CardioVascular Disease risk FACtors Two-township Study 709 
 710 
 711 
KORA, kooperative gesundheitsforschung in der region Augsburg; EFS-Y2D; DGI, Diabetes Genetics Initiative; Norfolk Diabetes Case Control Study, NDCCS; METSIM, 712 
Metabolic Syndrome in Men; DIAGEN, DIAbetes GENetic Study  713 
 714 
CHS, Cardiovascular Health Study  715 
 716 
WHI-OS, Women’s Health Initiative Observational Study Cohort 717 
 718 
ADDITION, Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care 719 
 720 
MONICA, Monitoring of Trends and Determinants in Cardiovascular Disease 721 
 722 
Genetics of Diabetes Audit and Research in Tayside Scotland, Go-DARTS 723 





Table 2: Nominally significance for each biomarker-associated genetic variants with glucose, HOMA-IR 727 
and the risk of type 2 diabetes  728 
   P value*  






 Nominally significance 
Adiponectin rs1736653 - - - NA 
rs2980879 0.96 0.9613 0.9276 Null 
rs16861209 0.89 0.846 0.505 Null 
rs601339 0.89 0.8344 0.02762 Yes 
rs17300539 0.87 0.8116 0.1489 Null 
rs7955516 0.86 0.8366 0.8286 Null 
rs12922394 0.54 0.07314 0.1932 Null 
rs3821799 0.51 0.1882 0.7989 Null 
rs731839 0.41 0.3386 0.01373 Yes 
rs3774261 0.32 0.4418 0.7559 Null 
rs17366568 0.31 0.9738 0.3994 Null 
rs7133378 0.16 0.2134 0.3286 Null 
rs12637534 0.15 0.379 0.0006 Yes 
rs6810075 0.1 0.7728 0.5248 Null 
rs998584 0.06 0.808 0.6827 Null 
rs1108842 0.032 0.4706 0.05447 Yes 
rs3001032 0.029 0.2725 0.0001 Yes 
rs1597466 0.0087 0.06167 0.4695 Yes 
rs2925979 0.0023 0.05063 0.1782 Yes 
Beta-carotene rs6564851 0.22 0.3938 0.2702 Null 
Bilirubin rs6742078 0.1 0.0239 0.03327 Yes 
B-type proBNP rs198389 0.034 0.3651 0.3891 Yes 
CRP rs1205 0.66 0.6836 0.6402 Null 
rs3093077 0.048 0.9494 0.393 Yes 
rs1130864 - 0.1199 0.7696 Null 
D6-desaturase rs174546 0.0032 2.7×10
-8
 0.8911 Yes 
Dimethylglycine rs2431332 0.51 0.00421 0.2899 Yes 
Ferritin/TMPRSS6 rs855791 1 0.09508 0.2457 Null 
rs4820268 0.73 0.1492 0.1271 Null 
Fetuin-a rs4917 0.082 0.1046 0.6666 Null 
rs2248690 0.055 0.9571 0.7713 Null 
Homocysteine rs4646356 0.88 0.4332 0.3475 Null 
rs12134663 0.78 0.6857 0.6192 Null 
rs1801131 0.22 0.6088 0.2367 Null 
rs1801133 0.096 0.459 0.4294 Null 
IL-1Ra rs1542176 0.64 0.00802 0.7087 Yes 
rs6743376 - 0.9109 0.4552 Null 
LTL rs12880583 - - - NA 
rs2228041 - - - NA 
rs34368910 - - - NA 
rs938886 0.88 0.04159 0.7375 Yes 
rs4975605 0.66 0.4506 0.6104 Null 
rs4888444 0.086 0.9143 0.3436 Null 
Lp(a) rs10455872 0.36 0.4242 0.3231 Null 
MIF rs1007888 0.39 0.2167 0.9401 Null 
miRNAs rs12610873 0.033 0.8022 0.7117 Yes 
rs531564 0.66 0.5302 0.9714 Null 
rs2910164 0.52 0.01256 0.3573 Yes 
Resistin rs3745367 0.77 0.9917 0.5793 Null 
rs1423096 0.72 0.8155 0.3391 Null 
SHBG rs12150660 0.18 0.5165 0.2413 Null 
rs6259 0.94 0.4235 0.3504 Null 
Triglycerides rs12285095 0.41 0.9737 0.6178 Null 
rs7557067 0.9 0.7824 0.1467 Null 
27 
 
rs7679 0.88 0.9 0.2909 Null 
rs2954029 0.72 0.6368 0.871 Null 
rs662799 0.28 0.04162 0.5552 Yes 
rs714052 0.28 0.807 0.8035 Null 
rs10889353 0.19 0.4164 0.2106 Null 
rs7819412 0.079 0.8028 0.00979 Yes 
rs328 0.025 0.05081 0.03923 Yes 
rs17216525 0.0035 0.9843 0.8103 Yes 
Uric acid rs1165151 0.74 0.4165 0.8597 Null 
rs2231142 0.73 0.8335 0.3608 Null 
rs505802 0.62 0.6034 0.6212 Null 
rs734553 0.57 0.1985 0.7163 Null 
rs742132 0.25 0.5028 0.9073 Null 
rs12356193 0.14 0.9486 0.4696 Null 
rs12129861 0.083 0.9366 0.502 Null 
rs17300741 0.026 0.3446 0.3608 Yes 
Vitamin-D rs10877012 - - - NA 
rs3755967 0.74 0.8454 0.1899 Null 
rs1155563 0.93 0.7691 0.06121 Null 
rs2298850 0.66 0.8892 0.1472 Null 
rs3829251 0.54 0.08705 0.2639 Null 
rs3794060 0.34 0.2832 0.1035 Null 
rs6599638 0.3 0.1749 0.4272 Null 
rs10741657 0.23 0.3746 0.0788 Null 
rs12785878 0.14 0.3232 0.1677 Null 
rs17217119 0.061 0.3553 0.2098 Null 
rs6013897 0.057 0.3293 0.1185 Null 
Vitamin D-BP rs2282679 0.76 0.997 0.1191 Null 
 729 
*p values for each of the biomarker variants were extracted from publicly available meta-analyses of genome-730 
wide association studies 
13, 14
. 731 
NA, not applicable; CRP, C-reactive protein; BNP, brain natriuretic peptide; interleukin 1 receptor antagonist 732 
(IL1-Ra); Lp(a)Lipoprotein(a);  MIF, Macrophage migration inhibitory factor; LTL, Leukocyte telomere length; 733 
SHBG, Sex hormone binding globulin, Vitamin D-BP, Vitamin D binding protein 734 
